Director-Affiliated Fund Liquidates $399.7M in Spyre Therapeutics Common Stock

summarizeSummary

A director-affiliated fund, Fairmount Healthcare Fund II L.P., sold nearly $400 million worth of Spyre Therapeutics common stock, liquidating its direct common stock holdings.

check_boxKey Events

• Director-Affiliated Fund Liquidates Common Stock Holdings

  Fairmount Healthcare Fund II L.P., associated with company directors, sold 4,684,781 shares of common stock for $399,658,667.11 at an average price of $85.31 per share, bringing its direct common stock ownership to zero. This represents 5.426% of the company's market capitalization.

• Conversion of Preferred Stock Preceded Sale

  Prior to the open market sale, Fairmount Healthcare Fund II L.P. converted 16,667 shares of Series B Preferred Stock into 666,680 shares of common stock for no cash consideration.

• Follows Recent Positive News and Offering

  This large sale occurs after Spyre Therapeutics reported highly positive Phase 2 clinical data for SPY001 and SPY002 in April and June, respectively, and completed a $435.3 million public offering in May.

auto_awesomeAnalysis

Fairmount Healthcare Fund II L.P., a fund associated with company directors, executed a substantial sale of Spyre Therapeutics common stock, liquidating its direct common stock holdings. This significant disposition, following a conversion of preferred shares, represents a material reduction in their stake and could be interpreted as a move to realize gains after recent positive clinical data and a successful public offering. While the fund still holds convertible preferred stock, the complete exit from common stock is a notable event.